Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

Table 1 Patient characteristics at study entry

Characteristic	L (n = 13)		L + R (n = 11)		L + other (n = 34)		Overall (N = 58)
Characteristic	No.	%	No.	%	No.	%	No.	%
Median age, years (range)	67 (54–83)		70 (58–84)		71 (50–89)		71 (50–89)
≥ 65	6	46	9	82	26	76	41	71
Sex
Male	11	85	8	73	25	74	44	76
Female	2	15	3	27	9	26	14	24
ECOG PS
0–1	7	54	5	45	16	47	28	48
2–4	3	23	1	9	4	12	8	14
Missing	3	23	5	45	14	41	22	38
Tumor burden^a
High	4	31	1	9	12	35	17	29
Low	1	8	5	45	13	38	19	33
Missing	8	62	5	45	9	26	22	38
Bulky disease^b
Yes	2	15	0	0	6	18	8	14
No	2	15	6	55	17	50	25	43
Missing	9	69	5	45	11	32	25	43
Time from diagnosis to first lenalidomide dose, months
Median	58		47		46		49
Range	15–144		6–105		4–214		4–214
Time from end of last prior antilymphoma therapy to first dose of lenalidomide, weeks
Median	0.7		0.3		0.7		0.7
Range	0.1–3.5		0.1–21.7		0.1–12.6		0.1–21.7

ECOG PS Eastern Cooperative Oncology Group performance status, L lenalidomide, L + R lenalidomide plus rituximab
^aHigh tumor burden is defined as at least one lesion ≥ 5 cm in diameter or three lesions ≥ 3 cm in diameter [22]
^bBulky disease is defined as at least one lesion ≥ 7 cm in the longest diameter²²

ISSN: 1756-8722